Efficacy of pembrolizumab for patients with both high PD‐L1 expression and an MET exon 14 skipping mutation: A case report

Efficacy of pembrolizumab for patients with both high PD‐L1 expression and an MET exon 14 skipping mutation: A case report

Pembrolizumab has become the standard first‐line treatment for non‐small cell lung cancer (NSCLC) patients with high PD‐L1expression. MET exon 14 skipping is a rare mutation typically found in older, female, and non‐smoking patients with NSCLC. Herein, we report the case of a 71‐year‐old non‐smoking...

Full description

Bibliographic Details
Main Authors: Keisuke Baba, Hisashi Tanaka, Hiroaki Sakamoto, Toshihiro Shiratori, Junichiro Tsuchiya, Yoshiko Ishioka, Masamichi Itoga, Kageaki Taima, Sadatomo Tasaka
Format: Article
Language:English
Published: Wiley 2019-02-01
Series:Thoracic Cancer
Subjects:
MET exon 14 skipping mutation
non‐small cell lung cancer
pembrolizumab
pemetrexed
programmed death‐ligand 1
Online Access:https://doi.org/10.1111/1759-7714.12939

Internet

https://doi.org/10.1111/1759-7714.12939

Similar Items